261 related articles for article (PubMed ID: 2161038)
1. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3.
Clark HF; Borian FE; Plotkin SA
J Infect Dis; 1990 Jun; 161(6):1099-104. PubMed ID: 2161038
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants.
Treanor JJ; Clark HF; Pichichero M; Christy C; Gouvea V; Shrager D; Palazzo S; Offit P
Pediatr Infect Dis J; 1995 Apr; 14(4):301-7. PubMed ID: 7603812
[TBL] [Abstract][Full Text] [Related]
3. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4.
Clark HF; Lawley D; Shrager D; Jean-Guillaume D; Offit PA; Whang SY; Eiden JJ; Bennett PS; Kaplan KM; Shaw AR
Pediatr Infect Dis J; 2004 Mar; 23(3):206-11. PubMed ID: 15014293
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season.
Clark HF; Borian FE; Bell LM; Modesto K; Gouvea V; Plotkin SA
J Infect Dis; 1988 Sep; 158(3):570-87. PubMed ID: 2842405
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants.
Bernstein DI; Smith VE; Sander DS; Pax KA; Schiff GM; Ward RL
J Infect Dis; 1990 Nov; 162(5):1055-62. PubMed ID: 2172394
[TBL] [Abstract][Full Text] [Related]
6. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group.
Bernstein DI; Glass RI; Rodgers G; Davidson BL; Sack DA
JAMA; 1995 Apr; 273(15):1191-6. PubMed ID: 7707626
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
Vesikari T; Matson DO; Dennehy P; Van Damme P; Santosham M; Rodriguez Z; Dallas MJ; Heyse JF; Goveia MG; Black SB; Shinefield HR; Christie CD; Ylitalo S; Itzler RF; Coia ML; Onorato MT; Adeyi BA; Marshall GS; Gothefors L; Campens D; Karvonen A; Watt JP; O'Brien KL; DiNubile MJ; Clark HF; Boslego JW; Offit PA; Heaton PM;
N Engl J Med; 2006 Jan; 354(1):23-33. PubMed ID: 16394299
[TBL] [Abstract][Full Text] [Related]
9. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants.
Clark HF; Offit PA; Ellis RW; Eiden JJ; Krah D; Shaw AR; Pichichero M; Treanor JJ; Borian FE; Bell LM; Plotkin SA
J Infect Dis; 1996 Sep; 174 Suppl 1():S73-80. PubMed ID: 8752294
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
Goveia MG; Rodriguez ZM; Dallas MJ; Itzler RF; Boslego JW; Heaton PM; DiNubile MJ;
Pediatr Infect Dis J; 2007 Dec; 26(12):1099-104. PubMed ID: 18043445
[TBL] [Abstract][Full Text] [Related]
13. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity.
Vesikari T; Ruuska T; Green KY; Flores J; Kapikian AZ
Pediatr Infect Dis J; 1992 Jul; 11(7):535-42. PubMed ID: 1326741
[TBL] [Abstract][Full Text] [Related]
14. Serotype 1 reassortant of bovine rotavirus WC3, strain WI79-9, induces a polytypic antibody response in infants.
Clark HF; Borian FE; Modesto K; Plotkin SA
Vaccine; 1990 Aug; 8(4):327-32. PubMed ID: 2168607
[TBL] [Abstract][Full Text] [Related]
15. Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses.
Jin Q; Ward RL; Knowlton DR; Gabbay YB; Linhares AC; Rappaport R; Woods PA; Glass RI; Gentsch JR
Arch Virol; 1996; 141(11):2057-76. PubMed ID: 8973523
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group.
Rennels MB; Glass RI; Dennehy PH; Bernstein DI; Pichichero ME; Zito ET; Mack ME; Davidson BL; Kapikian AZ
Pediatrics; 1996 Jan; 97(1):7-13. PubMed ID: 8545227
[TBL] [Abstract][Full Text] [Related]
17. Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children.
Kapikian AZ; Flores J; Hoshino Y; Midthun K; Gorziglia M; Green KY; Chanock RM; Potash L; Sears SD; Clements ML
Rev Infect Dis; 1989; 11 Suppl 3():S539-46. PubMed ID: 2548276
[TBL] [Abstract][Full Text] [Related]
18. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
Dennehy PH; Goveia MG; Dallas MJ; Heaton PM
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S36-42. PubMed ID: 18162245
[TBL] [Abstract][Full Text] [Related]
19. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis.
Joensuu J; Koskenniemi E; Pang XL; Vesikari T
Lancet; 1997 Oct; 350(9086):1205-9. PubMed ID: 9652561
[TBL] [Abstract][Full Text] [Related]
20. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups.
Madore HP; Christy C; Pichichero M; Long C; Pincus P; Vosefsky D; Kapikian AZ; Dolin R
J Infect Dis; 1992 Aug; 166(2):235-43. PubMed ID: 1321858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
